ADC Therapeutics SA
For the period ended Dec 31, 2025. Filed Mar 10, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 10, 2026
ADCT$1.67+5.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. Properties
We do not own any real property. The table below sets forth the sizes and uses of our leased facilities as of the date of this Annual Report:
| Location | Primary Function | Approximate Size |
|---|---|---|
| BiopôleRoute de la Corniche 3B 1066 Epalinges Switzerland | Head office | 292 m2 |
| 430 Mountain Avenue, 4th Floor New Providence, New Jersey 07974 United States | Clinical, commercial and U.S. operations | 965 m2 |
We are not aware of any environmental issues or other constraints that would materially impact the intended use of our facilities.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.